News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
Pharmalucence, Inc. Announces FDA Approval for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Breast Cancer Patients
July 25, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BEDFORD, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Rare diseases
FDA’s Prasad Vows to Make Rare Disease Drugs Available at ‘First Sign of Promise’
June 4, 2025
·
2 min read
·
Nick Paul Taylor
Podcast
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
June 4, 2025
·
2 min read
·
Heather McKenzie
Cancer
Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax
June 3, 2025
·
1 min read
·
Dan Samorodnitsky
Vaccines
Moderna Wins FDA Approval for Next-Gen COVID-19 Vaccine Despite ‘Investor Nervousness’
June 2, 2025
·
3 min read
·
Nick Paul Taylor